Intratumoral and Microenvironmental Heterogeneity in Patient Outcome Prediction.
作者信息
Beckman Robert A, Makohon-Moore Alvin P, Puzanov Igor
机构信息
Departments of Oncology and of Biostatistics, Bioinformatics, and Biomathematics, Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, DC.
Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ.
出版信息
JCO Precis Oncol. 2023 Feb;7:e2200698. doi: 10.1200/PO.22.00698.
Abstract
摘要
相似文献
1
Intratumoral and Microenvironmental Heterogeneity in Patient Outcome Prediction.患者预后预测中的肿瘤内及微环境异质性
JCO Precis Oncol. 2023 Feb;7:e2200698. doi: 10.1200/PO.22.00698.
2
Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non-small cell lung cancers.T4N0M0（直径≥7cm）非小细胞肺癌中的肿瘤内遗传和免疫微环境异质性。
Thorac Cancer. 2022 May;13(9):1333-1341. doi: 10.1111/1759-7714.14393. Epub 2022 Apr 8.
3
Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis.微环境异质性与乳腺癌进展并行：一项组织学-基因组整合分析
PLoS Med. 2016 Feb 16;13(2):e1001961. doi: 10.1371/journal.pmed.1001961. eCollection 2016 Feb.
4
Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective.从三维全肿瘤角度看胶质母细胞瘤的演变和异质性。
Cell. 2024 Jan 18;187(2):446-463.e16. doi: 10.1016/j.cell.2023.12.013.
5
Value of the Tumor-Stroma Ratio and Structural Heterogeneity Measured by a Novel Semiautomatic Image Analysis Technique for Predicting Survival in Patients With Colon Cancer.一种新型半自动图像分析技术测量的肿瘤-基质比和结构异质性在预测结肠癌患者生存中的价值
Dis Colon Rectum. 2023 Nov 1;66(11):1449-1461. doi: 10.1097/DCR.0000000000002570. Epub 2022 Dec 15.
6
Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma.瘤内代谢异质性及定量18F-FDG PET/CT参数对预测人乳头瘤病毒阳性的原发性口咽鳞状细胞癌患者预后的价值
Clin Nucl Med. 2017 May;42(5):e227-e234. doi: 10.1097/RLU.0000000000001578.
7
Effect of host age on microenvironmental heterogeneity and efficacy of combined modality therapy in solid tumors.宿主年龄对实体瘤微环境异质性及综合治疗疗效的影响。
Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):259-63. doi: 10.1016/0360-3016(91)90101-9.
8
Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer.胃癌中 HER2 免疫组织化学表达的肿瘤内和肿瘤间异质性。
Pathol Res Pract. 2020 Nov;216(11):153229. doi: 10.1016/j.prp.2020.153229. Epub 2020 Sep 21.
9
Intratumoral DNA heterogeneity correlated with lymph node involvement and surgical staging in epithelial ovarian cancer by flow cytometry.通过流式细胞术检测发现，上皮性卵巢癌瘤内DNA异质性与淋巴结受累及手术分期相关。
Cancer. 1994 Jun 15;73(12):3011-4. doi: 10.1002/1097-0142(19940615)73:12<3011::aid-cncr2820731219>3.0.co;2-9.
10
引用本文的文献
1
Reply to M. Younes.回复尤尼斯先生。
JCO Precis Oncol. 2023 Jun;7:e2300170. doi: 10.1200/PO.23.00170.
本文引用的文献
1
Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?评估免疫治疗期间个体病灶动力学增加的变异性：它是否存在，以及是否重要？
JCO Precis Oncol. 2023 Feb;7:e2200368. doi: 10.1200/PO.22.00368.
2
How Should Cancer Models Be Constructed?癌症模型应该如何构建？
Cancer Control. 2020 Jan-Dec;27(1):1073274820962008. doi: 10.1177/1073274820962008.
3
Rare Mutations in Cancer Drug Resistance and Implications for Therapy.癌症耐药中的罕见突变及其对治疗的影响
Clin Pharmacol Ther. 2020 Sep;108(3):437-439. doi: 10.1002/cpt.1938. Epub 2020 Jul 10.
4
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.肿瘤微环境对免疫检查点阻断治疗的反应。
Front Immunol. 2020 May 7;11:784. doi: 10.3389/fimmu.2020.00784. eCollection 2020.
5
Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis.液体活检中的肿瘤循环组学用于癌症的诊断和预后。
Theranostics. 2020 Mar 15;10(10):4544-4556. doi: 10.7150/thno.40532. eCollection 2020.
6
Extensive subclonal mutational diversity in human colorectal cancer and its significance.人类结直肠癌中广泛的亚克隆突变多样性及其意义。
Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26863-26872. doi: 10.1073/pnas.1910301116. Epub 2019 Dec 5.
7
An analysis of genetic heterogeneity in untreated cancers.未治疗癌症中的遗传异质性分析。
Nat Rev Cancer. 2019 Nov;19(11):639-650. doi: 10.1038/s41568-019-0185-x. Epub 2019 Aug 27.
8
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer.胰腺癌个体患者转移灶中已知驱动基因突变的异质性有限。
Nat Genet. 2017 Mar;49(3):358-366. doi: 10.1038/ng.3764. Epub 2017 Jan 16.
9
Comparison of CT volumetric measurement with RECIST response in patients with lung cancer.肺癌患者CT容积测量与RECIST反应的比较。
Eur J Radiol. 2016 Mar;85(3):524-33. doi: 10.1016/j.ejrad.2015.12.019. Epub 2016 Jan 2.
10
The influence of subclonal resistance mutations on targeted cancer therapy.亚克隆耐药突变对靶向癌症治疗的影响。
Nat Rev Clin Oncol. 2016 Jun;13(6):335-47. doi: 10.1038/nrclinonc.2015.175. Epub 2015 Oct 20.
Zotero 插件